Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Mesenchymal Stem Cells in Multiple System Atrophy
NCT05167721Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous mesenchymal stem cells in multiple system atrophy (MSA) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Unified Multiple System Atrophy Rating Scale total score at 12 months. Started Dec 2021; status: active, not recruiting.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT05167721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167721.